How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Victoire Fokom Defo, MD and Joël Fokom Domgue, MD, MPH
HPV tests are alternatives to Pap smear screening that enable women to self-collect specimens and might be the best cervical cancer prevention strategy for many.
AMA J Ethics. 2020;22(2):E116-125. doi:
10.1001/amajethics.2020.116.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.